Immunomodulation by thalidomide and thalidomide analogues (Q33782386)

29 July 2017

1 reference

title

Immunomodulation by thalidomide and thalidomide analogues (English)

1 reference

29 July 2017

0 references

Corral LG

1

1 reference

PubMed ID

10577986

29 July 2017

Kaplan G

series ordinal

2

1 reference

PubMed ID

10577986

29 July 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

Annals of the Rheumatic Diseases

29 July 2017

1 reference

29 July 2017

58 Suppl 1

1 reference

29 July 2017

I107-13

1 reference

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Thalidomide, a current teratogen in South America

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

High frequency of CD8+ cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Thalidomide: rationale for renewed use in immunological disorders

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Nuclear factor kappa B, a mediator of lipopolysaccharide effects

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Cytokine mediators of septic infections in the normal and granulocytopenic host

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Impaired interleukin 12 production in human immunodeficiency virus-infected patients

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA)

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

HIV gp120 inhibits T cell activation by interfering with expression of costimulatory molecules CD40 ligand and CD80 (B71)

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

The Role of CD40 and its Ligand in the Regulation of the Immune Response

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Thalidomide is an inhibitor of angiogenesis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Excitation of area postrema neurons by transmitters, peptides, and cyclic nucleotides.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

HIV enhancer activity perpetuated by NF-kappa B induction on infection of monocytes

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Tumor necrosis factor and regulation of metabolism in infection: role of systemic versus tissue levels

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Initiation and maintenance of multiple myeloma.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Perspectives on the role of CD8+ cell suppressor factors and cytotoxic T lymphocytes during HIV infection.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Control of Leishmania major infection in mice lacking TNF receptors.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766578

Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells

30 October 2018

1 reference

12 December 2020

Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis

1 reference

12 December 2020

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent

1 reference

12 December 2020

CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production

1 reference

12 December 2020

Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease

1 reference

12 December 2020

Thalidomide in oral Crohn's disease refractory to conventional medical treatment

1 reference

12 December 2020

Inhibition of IL-12 production by thalidomide

1 reference

12 December 2020

Thalidomide in Crohn's disease

1 reference

12 December 2020

Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease

1 reference

12 December 2020

Thalidomide protects mice against LPS-induced shock

1 reference

12 December 2020

CD40 ligand and IFN-gamma synergistically restore IL-12 production in HIV-infected patients

1 reference

12 December 2020

Treatment of ulcerative colitis with thalidomide

1 reference

12 December 2020

Thalidomide for the treatment of chronic graft-versus-host disease

1 reference

12 December 2020

Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents

1 reference

12 December 2020

Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis

1 reference

12 December 2020

Thalidomide analogs and PDE4 inhibition

1 reference

12 December 2020

HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines

1 reference

12 December 2020

Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease

1 reference

12 December 2020

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

1 reference

12 December 2020

Inhibition of T lymphocyte activation by cAMP is associated with down-regulation of two parallel mitogen-activated protein kinase pathways, the extracellular signal-related kinase and c-Jun N-terminal kinase

1 reference

12 December 2020

Antigen-driven but not lipopolysaccharide-driven IL-12 production in macrophages requires triggering of CD40

1 reference

12 December 2020

Dendritic epidermal T-cell involvement in induction of CD8+ T cell-mediated immunity against an ultraviolet radiation-induced skin tumor

1 reference

12 December 2020

Protection from T cell-mediated murine liver failure by phosphodiesterase inhibitors

1 reference

12 December 2020

Regulation of T cell-dependent and -independent IL-12 production by the three Th2-type cytokines IL-10, IL-6, and IL-4

1 reference

12 December 2020

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

1 reference

12 December 2020

The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum Leprosum

1 reference

12 December 2020

Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro

1 reference

12 December 2020

Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors

1 reference

12 December 2020

Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.58.2008.I107

1 reference

release_ua6djmy2tva75ecbcix36xq3ra

29 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ua6djmy2tva75ecbcix36xq3ra

24 November 2022

mapped directly with Wikidata item

PMCID

1766578

1 reference

29 July 2017

1 reference

PubMed ID

10577986